Company intelligence / Profile preview
Innovacell
- Ownership
- Private
- Development stage
- Other
Overview
Innovacell is a late-stage biotech company developing cell therapies for incontinence using autologous skeletal muscle cells[3]. The lead program, ICEF15, is currently in a Phase 3 multi-regional clinical trial for urge fecal incontinence across Europe and Japan[3]. The company operates a state-of-the-art GMP manufacturing facility in Innsbruck, Austria, with commercial capacity of approximately 2,500 units per annum and potential to expand to 70,000 units annually[5].
- Therapeutic areas
- Women's HealthGastroenterology
- Modalities
- Cell therapyStem cell therapy
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Innovacell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innovacell.